The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of crizotinib in ROS1-rearranged lung cancer: The European experience.
Julien Mazieres
No relevant relationships to disclose
Gerard Zalcman
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Lucio Crino
No relevant relationships to disclose
Pamela Biondani
No relevant relationships to disclose
Benjamin Besse
Research Funding - Pfizer
Anne-Marie C. Dingemans
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; Pfizer; Roche
Honoraria - Pfizer
Hervé Lena
Consultant or Advisory Role - Pfizer
Other Remuneration - Pfizer
Isabelle Monnet
No relevant relationships to disclose
Sacha Rothschild
No relevant relationships to disclose
Federico Cappuzzo
No relevant relationships to disclose
Luc Thiberville
No relevant relationships to disclose
Damien Rouvière
No relevant relationships to disclose
Rafal Dziadziuszko
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Egbert F. Smit
No relevant relationships to disclose
Juergen Wolf
No relevant relationships to disclose
Christian Spirig
No relevant relationships to disclose
Nicolas Pécuchet
No relevant relationships to disclose
Joachim Diebold
No relevant relationships to disclose
Julie Milia
No relevant relationships to disclose
Oliver Gautschi
Consultant or Advisory Role - Pfizer